Skip to content
ATLAS PREP HQ
Growth Hormone

GHRP-6

Growth hormone-releasing peptide-6, a synthetic ghrelin-receptor agonist hexapeptide

Ghrelin-mimetic peptide research examining growth-hormone release and ghrelin-receptor signaling.

Limited Human Evidence

Route

Subcutaneous.

Common format

5 mg vial

Research focus

GH secretion

Evidence level

Limited Human Evidence

Typical cycle

8–12 weeks

Growth Hormone research motifGrowth Hormone

GHRP-6 in 30 seconds

Atlas Fast Read

What it is

Growth hormone-releasing peptide-6, a synthetic ghrelin-receptor agonist hexapeptide

Why people care

Ghrelin-mimetic peptide research examining growth-hormone release and ghrelin-receptor signaling.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

GHRP-6 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is GHRP-6?

GHRP-6 is growth hormone-releasing peptide-6, a synthetic ghrelin-receptor agonist hexapeptide. Ghrelin-mimetic peptide research examining growth-hormone release and ghrelin-receptor signaling.

GHRP-6 was one of the early synthetic growth-hormone-releasing peptides developed before the ghrelin receptor was fully characterized. Its appetite-stimulating effect helped link this peptide class to ghrelin biology.

Mechanism

How it works

Agonizes GHSR-1a, stimulating GH release and strongly engaging ghrelin-like appetite signaling. Preclinical work also suggests CD36-related cytoprotective pathways.

Research areas

GH secretionappetite stimulationtissue protectionbody composition

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human studies demonstrate acute GH release and appetite effects from GHRP-6. Evidence for long-term recovery, muscle-building, anti-aging, or organ-protective outcomes remains limited.

Preclinical evidence

Preclinical studies support GHSR-mediated GH release, orexigenic effects, and possible cytoprotective/cardiac pathways. Human evidence primarily confirms GH and appetite effects.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 100–300 mcg per injection, three times daily (300–900 mcg/day total).

Frequency

Three times daily in the community page, spaced at least 4 hours apart.

Timing

Morning, midday and bedtime, generally fasted around dosing in the community sources protocol.

Route

Subcutaneous.

Cycle length

8–12 weeks

Reconstitution

Community reference: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within about 7 days.

Monitoring

IGF-1, fasting glucose/HbA1c, appetite/weight, edema and BP; cortisol/prolactin can be considered if symptoms suggest off-target endocrine effects.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in some secretagogues, and worsening glucose tolerance. Injection-site reactions can occur. GHRP-6 can markedly increase hunger and may affect cortisol/prolactin.

Contraindications

Avoid in active malignancy and use extreme caution with uncontrolled diabetes, proliferative retinopathy, untreated pituitary disease, pregnancy/breastfeeding or significant edema. Exact contraindications are not established for research formulations.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

GHRP-6 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide